Hot search: insulation  pneumatic  motor  hydraulic  fuel 

ALK Fusion Probe

Click on the image to check the artwork
unit price: negotiable
min amount:
period for delivery: Consignment Deadline Days
area: Hubei
Expiry date : Long Effective
last update: 2018-09-07 17:37
view count: 342
Company Profile
Product details

◆ALK Gene Fusion Detection Probe

◆Product Advantages:  

1.Fleetness: Tissue probe hybridization time: 2 hours. Cell probe hybridization time: 1 hour. 

2.Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate. 

3.Reproducibility: Different laboratories test results are highly reproducible.


◆About ALK

The ALK gene encodes a transmembrane receptor tyrosine kinase (RTK). The ALK-NPM1 fusion protein was originally found in anaplastic large cell lymphoma and in other tumors including neuroblastoma and non-small cell lung cancer. The gene was found to be mutated, amplified, or rearranged, with chromosome rearrangements being the most common, resulting in ALK fusion with other genes including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3) , ALK / NPM1 (chromosome 5), ALK / SQSTM1 (chromosome 5), ALK / KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (X chromosome).


Probe Description

ALK gene break apart probe uses orange labeled dye ALK gene (3 ' End) 2p23.2 region, and a green dye ALK gene (5' End) to mark 2p23.1-p23.2 region. ALK gene break apart probe can detect all ALK gene rearrangement, avoiding missed diagnosis caused by a single fusion gene (such as EML4-ALK). The 2013 edition of China anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer diagnosis expert consensus pointed out that adenocarcinoma, for age (60 years old), nonsmoking, EGFR, KRAS, HER2 or P53 in patients without NSCLC gene mutations, ALK gene positive rate is high as 30%~ 42%. Pathological studies suggest that the positive rate in signet-ring cell-containing mucinous or solid adenocarcinoma is higher than other types of lung adenocarcinoma. In 2013, CFDA approved XALKORI (Crizotinib) for targeted therapy of advanced ALK-positive non-small cell lung cancer, and the necessary condition for XALKORI (Crizotinib) drug treatment was FISH for the detection of ALK-positive non-small cell lung cancer. ALK-positive gene fusion patients are sensitive to XALKORI (Crizotinib) treatment.



Size Specifications

References :

l  Rodig SJ, et al. (2009) Clin Cancer Res 15: 5216-23.

l  Sasaki T, et al. (2010) Eur J Cancer 46: 1773-80.

l  Von Laffert M, et al. (2013) Lung Cancer 81: 200-6.

Total0bar [View All]  Related Comments
More>other products

[ ProductsSearch ]  [ Send Fav ]  [ Share ]  [ Print ]  [ Send Report ]  [ Close ]

Home | Products | Suppliers | News | Tradeshow | Sitemap | Message | RSS Feed